natgillin/translations-raw huggingface dataset:
Desuden kan Imatinib Accord 100 mg tabletter fås i perforeret enhedsdosis-blister af PVC/PVdC/alu i pakningsstørrelser med 30 x 1, 60 x 1, 90 x 1, 120 x 1 eller 180 x 1 filmovertrukne tabletter.
Additionally Imatinib Accord 100 mg tablets are available in PVC/PVdC/Alu perforated unit dose blister in pack-sizes of 30x1, 60x1, 90x1, 120x1 or 180x1 film-coated tablets.
Desuden kan Imatinib Accord 400 mg tabletter fås i perforeret enhedsdosis-blister af PVC/PVdC/alu i pakningsstørrelser med 30 x 1, 60 x 1 eller 90 x 1 filmovertrukne tabletter.
Additionally Imatinib Accord 400 mg tablets are available in perforated unit dose blister packs (PVC/PVdC/Alu) containing 30x1, 60x1or 90x1 film-coated tablets.
Desuden kan Imatinib Accord 400 mg tabletter fås i perforeret enhedsdosis-blister af PVC/PVdC/alu i pakningsstørrelser med 30 x 1, 60 x 1 eller 90 x 1 filmovertrukne tabletter.
Additionally Imatinib Accord 400mg tablets are available in PVC/PVdC/Alu perforated unit dose blister in pack-sizes of 30x1, 60x1 or 90x1 film-coated tablets.
Desuden kan Oncaspar gennem inhibering af proteinsyntesen og celledelingen forstyrre virkningsmekanismen for andre stoffer, som bruger celledeling som en del af virkningen, f.eks. methotrexat.
In addition, by inhibiting protein synthesis and cell division, Oncaspar can disturb the mechanism of action of other substances which require cell division for their effect, e.g. methotrexate.
Desuden kan overstimulering af NMDA- receptorerne medføre cellebeskadigelse eller -død.
In addition, overstimulation of the NMDA receptors may result in cell damage or death.
Desuden kan patienterne udvikle antistoffer mod faktor VIII og von Willebrand-faktor.
Furthermore, patients may develop antibodies against factor VIII and von Willebrand factor.
Desuden kan personer, som udviklede trombocytopeni efter den 1. dosis
In addition, individuals who experienced thrombocytopenia with the first dose of
Desuden kan samtidig sygdom, især infektioner, føre til hyperglykæmi og derved forårsage et øget behov for diabetesbehandling.
Furthermore, concomitant illness, especially infections, may lead to hyperglycaemia and thereby cause an increased requirement for anti- diabetic treatment.
Desuden kan telithromycin blokere dannelsen af 50S og 30S ribosomale subunits.
Furthermore, telithromycin is able to block the formation of the 50S and 30S ribosomal subunits.
Desuden kan tenofovir øge raltegravirs plasmakoncentrationer, men mekanismen for denne effekt er ukendt (se tabel 1).
In addition, tenofovir may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 1).
Desuden kan tenofovir øge raltegravirs plasmakoncentrationer, men mekanismen for denne effekt er ukendt (se tabel 2).
In addition, tenofovir may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 2).
Desuden kan tenofovir øge raltegravirs plasmakoncentrationer, men mekanismen for denne effekt er ukendt (se tabel 3).
In addition, tenofovir may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 3).
Desuden kan test vise nedsat fosfatindhold (almindeligt) eller øget kreatininindhold (meget almindeligt) i blodet.
Also tests may show decreases in phosphate (common) or increases in creatinine (very common) in the blood.
Desuden kan Viread medføre et fald i knoglemassen.
Moreover, Viread may cause a reduction in bone density.
Desuden konkluderede CHMP, at Eylea var effektivt til at forbedre synsevnen hos patienter med makulært ødem som følge af CRVO, BRVO eller diabetes såvel som hos patienter med koroidal neovaskularisering forårsaget af myopi.
In addition the CHMP considered that Eylea was beneficial in improving vision of patients with macular oedema resulting from CRVO, BRVO or diabetes as well as patients with myopic choroidal neovascularisation.
Desuden krævede CHMP, at der blev udført en supplerende undersøgelse til bekræftelse af, at den nuværende anbefalede dosis er den mest hensigtsmæssige.
In addition, the CHMP required that an additional study should be carried out to confirm that the current recommended dose is the most appropriate dose.
Desuden levede patienter behandlet med Xtandi længere, uden at deres sygdom viste tegn på forværring ved røntgen: 19,7 måneder sammenlignet med 5,4 måneder for patienter behandlet med placebo.
In addition patients treated with Xtandi lived for longer without their disease showing signs of worsening in a radiographic scan: 19.7 months compared with 5.4 months for patients treated with placebo.
Desuden mindskedes antallet af hvide blodlegemer med Philadelphia-kromosomet hos mellem en tredjedel og to tredjedele af patienterne i de fem hovedundersøgelser.
In addition, between one and two thirds of the patients in the five main trials showed a reduction in the number of white blood cells containing the Philadelphia chromosome.
Desuden må den fyldte pen ikke efterlades i direkte sollys.
Additionally, do not leave the pre-filled pen exposed to direct sunlight.
Desuden måtte patienter med PKU, som ikke var på en diæt, indtage 17,5 mg fenylalanin pr. kg kropsvægt mere om dagen efter 10 uger sammenlignet med 3,3 mg pr. kg mere for de børn, der fik placebo.
In addition Kuvan allowed patients with PKU who were not on a diet restriction to increase their daily phenylalanine intake by 17.5 mg per kg body weight after 10 weeks compared with 3.3 mg/kg with placebo.
Desuden observeredes forøget forekomst af knoglefrakturer hos kvinder i behandling med rosiglitazon (se afsnit 4.4 og 4.8).
was seen in women with rosiglitazone (see sections 4.4 and 4.8).
Desuden omfattede nogle af disse positiv rechallenge (symptomer kom igen ved reeksponering) og dechallenge (symptomer forsvandt ved seponering).
Furthermore, some of these included positive rechallenge and dechallenge.
Desuden omfatter rapporterne vedrørende Oncaspar efter markedsføringen både spontan rapportering og alvorlige bivirkninger fra kliniske studier.
In addition, the post-marketing reports with Oncaspar that include spontaneous reports as well as serious adverse events from clinical studies.
Desuden ophæver det delvist reduktionen i GABA- og glycin -medierede strømme, induceret af zink og β- carboliner.
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines.
Desuden ophæver det delvist reduktionen i GABA- og glycin -medierede strømme, induceret af zink og β- carboliner.
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and - carbolines.
Desuden ophæver det delvist reduktionen i GABA- og glycin -medierede strømme, induceret af zink og β- carboliner.
In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β- carbolines.
Desuden ophæver det delvist reduktionen i GABA- og glycin -medierede strømme, induceret af zink og β- carboliner.
In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines.
Desuden ophæver det delvist reduktionen i GABA- og glycin medierede strømme induceret af zink og β-carboliner.
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β- carbolines.
Desuden ophæver det delvist reduktionen i GABA- og glycin-medierede strømme induceret af zink og β- carboliner.
In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines.
Desuden ophæver det delvist reduktionen i GABA- og glycin-medierede strømme, induceret af zink og β- carboliner.
In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and -carbolines.
Desuden oplevede 74 % af de patienter, der blev behandlet med Soliris, klinisk betydningsfulde forbedringer i FACIT-træthedsscoren (dvs. en stigning på 4 point eller mere), og 84 % oplevede en forbedring i EORTC-træthedsscoren (dvs. et fald på 10 point eller mere).
Furthermore, 74% of the patients treated with Soliris experienced clinically meaningful improvements in FACIT-Fatigue score (i.e., increase by 4 points or more) and 84% in EORTC fatigue score (i.e., decrease by 10 points or more).
Desuden oplevede de patienter, der blev behandlet med Daxas, gennemsnitlig 1,1 moderat eller svært tilfælde af sygdomsopblussen sammenlignet med 1,4 hos de patienter, der fik placebo.
In addition, the patients who took Daxas had an average of 1.1 moderate or severe flare-ups of their disease, compared with 1.4 flare-ups in the patients who took placebo.
Desuden opstod der forhøjet aktivitet i glutamat-pyrovattransferase i serum i én af fire hunde.
Increased serum glutamic pyruvic transaminase activity also occurred in one of four dogs.
Desuden opstår der hos mere end 1 ud af 100 patienter med type 2- diabetes og nyresygdom følgende bivirkninger: hyperkaliæmi (højt indhold af kalium i blodet), ortostatisk svimmelhed (svimmelhed i stående stilling), ortostatisk hypotension (lavt blodtryk i stående stilling) og muskel- og ledsmerter.
In addition, more than 1 patient in 100 with type 2 diabetes and kidney disease has the following side effects: hyperkalaemia (high blood potassium levels), orthostatic dizziness (dizziness when standing up), orthostatic hypotension (low blood pressure when standing up) and musculoskeletal (joint) pain.
Desuden påvirkede fludarabin og cyklofosfamid tilsyneladende ikke farmakokinetikken af MabThera.
In addition, there was no apparent effect of fludarabine and cyclophosphamide on the pharmacokinetics of MabThera.
Desuden rapporterede patienter med erektil dysfunktion i alle sværhedsgrader forbedrede erektioner, når de tog tadalafil (86 %, 83 % og 72 % for henholdsvis mild, moderat og svær i forhold til 45 %, 42 % og 19 % for placebo).
Also, patients with erectile dysfunction in all severity categories reported improved erections whilst taking tadalafil (86%, 83%, and 72% for mild, moderate and severe respectively, as compared to 45%, 42% and 19% with placebo).
Desuden refererer produktresumeerne for peginterferon alfa-2b og interferon alfa-2b til bivirkninger, der kan tilskrives interferoners monoterapi.
Also, refer to peginterferon alfa- 2b and interferon alfa-2b SmPCs for adverse reactions that may be attributable to interferons monotherapy.
Desuden refererer SPC'et for peginterferon alfa- 2b og interferon alfa-2b til bivirkninger, der kan tilskrives interferonmonoterapi.
Also, refer to peginterferon alfa-2b and interferon alfa-2b SPCs for adverse reactions that may be attributable to interferon monotherapy.
Desuden refererer SPC'et for peginterferon alfa-2b og interferon alfa-2b til bivirkninger, der kan tilskrives interferonmonoterapi.
Also, refer to peginterferon alfa- 2b and interferon alfa-2b SPCs for adverse reactions that may be attributable to interferon monotherapy.
Desuden sammenlignede man i en anden hovedundersøgelse, der omfattede 605 patienter med PAH, kombinationen af Volibris (10 mg) og tadalafil med enten Volibris eller tadalafil alene.
In addition, treatment with a combination of Volibris (10 mg) and tadalafil has been compared with either Volibris or tadalafil alone in another main study involving 605 patients with PAH.
Desuden skal den virksomhed, der fremstiller Iclusig, udlevere informationsmateriale til alle læger, som forventes at ordinere dette lægemiddel, med en beskrivelse af visse alvorlige risici, for hvilke der anbefales overvågning og dosisjustering.
In addition, the company that markets Iclusig will provide educational material for all doctors who are expected to prescribe this medicine highlighting important risks for which monitoring and dose adjustments are recommended.
Desuden skal den virksomhed, der fremstiller Pradaxa, udlevere en informationspakke til alle læger, som forventes at ordinere lægemidlet, for at øge bevidstheden om risikoen for blødning og give instruktioner i, hvordan denne risiko skal håndteres.
In addition, the company that makes Pradaxa will provide an educational pack for all doctors who are expected to prescribe the medicine, to increase awareness of the risk of bleeding and provide guidance on how to manage it.
Desuden skal den virksomhed, der markedsfører Cerdelga, udlevere oplysningsmateriale til læger og patienter for at sikre, at kun patienter med Gauchers sygdom type 1 behandles med Cerdelga, og at Cerdelga ikke anvendes sammen med andre lægemidler, der kan påvirke dets koncentration i blodet væsentligt.
In addition, the company that markets Cerdelga will provide doctors and patients with educational materials to ensure that only patients with type-1 Gaucher disease are treated with Cerdelga and that Cerdelga is not used together with other medicines which can significantly alter its blood levels.
Desuden skal den virksomhed, der markedsfører Cubicin, udlevere et dosiskort til alle læger for at sikre risikofri brug af lægemidlet.
In addition, the company that markets Cubicin will provide all doctors who are expected to use Cubicin with a dosage card to ensure the safe use of the medicine.
Desuden skal den virksomhed, der markedsfører Deltyba, udlevere oplysningsmateriale til sundhedspersoner med forklaring af, hvordan lægemidlet anvendes risikofrit for at undgå problemer såsom resistensudvikling og bivirkninger fra hjertet samt risiciene ved graviditet og amning.
In addition, the company that markets Deltyba will provide educational material for healthcare professionals, explaining how to use the medicine safely in order to avoid problems such as the development of resistance and side effects on the heart, as well as the risks in pregnancy or women who are breast-feeding.
Desuden skal den virksomhed, der markedsfører Eliquis, udlevere oplysningsmateriale til de sundhedspersoner, der forventes at udskrive Eliquis, med henblik på at redegøre for risikoen for blødning under behandlingen.
In addition, the company that markets Eliquis will provide educational material for healthcare professionals expected to prescribe Eliquis that addresses the risk of bleeding during treatment.
Desuden skal den virksomhed, der markedsfører Ivabradine Anpharm, foretage en yderligere undersøgelse af de patienter, der anvender lægemidlet, hvordan det anvendes, og hvor godt foranstaltningerne til mindskelse af risiciene ved behandlingen overholdes.
In addition, the company that markets Ivabradine Anpharm must carry out a further study of the patients using the medicine and the way that it is used, and of how well measures to reduce the risks of treatment are being followed.
Desuden skal den virksomhed, der markedsfører Lynparza, udføre yderligere undersøgelser af lægemidlets fordele ved æggestokkræft, herunder de langsigtede fordele.
In addition, the company that markets Lynparza will carry out studies to further confirm the benefit, including long-term benefit of the medicine in patients with ovarian cancer.
Desuden skal den virksomhed, der markedsfører lægemidlet, udføre en nærmere undersøgelse af Lonquex’ virkning på patienternes kræftsygdom – muligheden for forværring af kræftsygdommen under behandling med G-CSF-lægemidler var en betænkelighed, der blev rejst under vurderingen af lægemidlet, men ikke blev bekræftet.
In addition, the company that markets the medicine will carry out a study to further investigate the effects of Lonquex on the patients’ cancer - the possibility of cancer worsening during treatment with G‑CSF medicines was a concern raised during the evaluation of the medicine though this was not established.
Desuden skal den virksomhed, der markedsfører Oncaspar, gennemføre to yderligere undersøgelser af sikkerheden og virkningen af Oncaspar for yderligere at klarlægge fordelene og risiciene ved dette lægemiddel hos voksne og hos nydiagnosticerede patienter.
In addition, the company that markets Oncaspar will complete two more studies on the safety and effectiveness of Oncaspar, which will help further clarify the benefits and risks of this medicine in adults and in newly diagnosed patients.
Desuden skal den virksomhed, der markedsfører Opsumit, udlevere informationsmateriale til patienter og sundhedspersoner om de forholdsregler, der skal træffes ved anvendelse af Opsumit.
In addition, the company that markets Opsumit will send educational material to patients and healthcare professionals with information on the precautions to be taken when using Opsumit.
Desuden skal den virksomhed, der markedsfører Relvar Ellipta, udføre yderligere undersøgelser af risikoen for lungebetændelse med dette lægemiddel sammenlignet med andre lægemidler mod KOL og astma.
In addition, the company that markets Relvar Ellipta will conduct further studies to investigate the risk of pneumonia with this medicine in comparison with other COPD and asthma medicines.
Desuden skal den virksomhed, der markedsfører Remsima, udlevere oplysningsmateriale til de læger, som forventes at ordinere lægemidlet til børn og voksne, herunder information om lægemidlets sikkerhed og et advarselskort, som skal udleveres til patienterne.
In addition, the company that markets Remsima will provide educational material to doctors who are expected to prescribe the medicine in adults and children, including information on the safety of the medicine and an alert card to be given to patients.
Desuden skal den virksomhed, der markedsfører Revinty Ellipta, udføre yderligere undersøgelser vedrørende risikoen for lungebetændelse forbundet med dette lægemiddel sammenlignet med andre lægemidler mod KOL og astma.
In addition, the company that markets Revinty Ellipta will conduct further studies to investigate the risk of pneumonia with this medicine in comparison with other COPD and asthma medicines.
Desuden skal den virksomhed, der markedsfører Sevelamer carbonate Zentiva, stille informationsmateriale til rådighed for patienter og sundhedspersoner i alle medlemsstater.
In addition, the company that markets Sevelamer carbonate Zentiva will make sure that educational material is available in all Member States for patients and healthcare professionals.
Desuden skal den virksomhed, der markedsfører Sylvant, oprette et patientregister, der skal levere flere oplysninger om sikkerheden ved langvarig brug.
Additionally, the company that markets Sylvant is required to set up a patient registry to provide further data on long-term safety.
Desuden skal den virksomhed, der markedsfører Xultophy, udlevere oplysningsmateriale til sundhedspersoner, hvori det forklares, hvordan lægemidlet skal anvendes sikkert for at nedsætte risikoen for fejlbehandling.
In addition, the company that markets Xultophy will provide educational materials for healthcare professionals, explaining how to use the medicine safely, so as to reduce the risk of medication errors.
Desuden skal der gøres opmærksom på, at tidligere infektioner kan blusse op igen. til at gøre opmærksom på risikoen for at patienter, som får RoActemra, kan udvikle komplikationer til diverticulitis, og at disse komplikationer kan blive alvorlige, hvis de ikke behandles. til at gøre opmærksom på risikoen for at få overfølsomhedsreaktioner.
In addition, some previous infections may reappear. to address the risk that patients using RoActemra may develop complications of diverticulitis which can become serious if not treated. to address the risk of allergic reactions.
Desuden skal der regelmæssigt tages prøver af blod og urin for at bestemme vigtige elektrolytter, så lægen kan tilpasse doserne af disse kosttilskud.
Regular blood and urine tests to measure the levels of the body’s important electrolytes are also necessary to help you or your doctor correctly adjust the doses of these supplements.
Desuden skal der udvises særlig forsigtighed hos patienter, som er prædisponerede for dybe venetromboser.
In addition, special precaution should be taken in patients with predisposition for development of DVTs.
Desuden skal det overvejes at give patienter med obstruktiv lungesygdom i anamnesen lægemidler efter infusionen som f.eks. bronkodilatorer med kort og lang virkningstid samt inhalationskortikosteroider.
Additionally, for patients with a history of obstructive pulmonary disorder, the use of post-infusion medications including short and long acting bronchodilators, and inhaled corticosteroids should be considered.
Desuden skal du bruge en affaldsbeholder til brugte injektionssprøjter og kanyler.
In addition you will need a disposal unit for used syringes and needles.
Desuden skal EKG og blodtryk kontrolleres under SonoVue-forstærket ekkokardiografi med samtidig brug af en farmakologisk stressor (for eksempel dobutamin).
Moreover, ECG and blood pressure monitoring should be performed during SonoVue-enhanced echocardiography with a pharmacological stress (e.g. with dobutamine).
Desuden skal en opdateret RMP indsendes
In addition, an updated RMP should be submitted
Desuden skal nyrefunktionen overvåges nøje med en hyppighed, som skal tilpasses efter den individuelle patients medicinske tilstand.
In addition, renal function should be closely monitored with a frequency tailored to the individual patient’s medical condition.
Desuden skal virksomheden udføre yderligere to undersøgelser af lægemidlets fordele samt en sikkerhedsundersøgelse hos en større gruppe patienter med HL og sALCL.
In addition, the company will carry out two further studies on the benefits of the medicine and a safety study in a larger population of HL and sALCL patients.
Desuden skal virksomheden udlevere oplysningsmateriale til patienter og omsorgsgivere for at sikre, at Strensiq anvendes korrekt, og at risikoen for medicineringsfejl bliver mindst mulig.
In addition, the company will provide patients and carers with educational materials to ensure that Strensiq is used correctly and to minimise the risk of medication errors.
Desuden skal virksomheden, der fremstiller Thymanax, udlevere informationsmateriale til de læger, som ordinerer Thymanax.
In addition, the company that makes Thymanax will supply educational material for doctors prescribing Thymanax.
Desuden skal virksomheden, der fremstiller Valdoxan, udlevere informationsmateriale til de læger, som ordinerer Valdoxan.
In addition, the company that makes Valdoxan will supply educational material for doctors prescribing Valdoxan.
Desuden skal virksomheden, der markedsfører MabThera, også indsende rapporter fra undersøgelser om MabTheras sikkerhed på længere sigt.
In addition, the company that markets MabThera will also submit reports from studies on the long- term safety of MabThera.
Desuden skal virksomheden, som fremstiller Exjade udarbejde en informationspakke til sundhedspersoner.
In addition, the company that makes Exjade must prepare an education pack for healthcare professionals.
Desuden skal virksomheden, som markedsfører Revolade, sikre, at læger i alle EU-medlemsstater, som ordinerer dette lægemiddel, får undervisningsmateriale, som indeholder oplysninger om, hvordan lægemidlet skal anvendes, og om lægemidlets mulige bivirkninger såsom leverproblemer, tromboemboliske komplikationer og gentagne blødninger.
In addition, the company that markets Revolade will ensure that doctors in all Member States who will prescribe the medicine are provided with educational materials reminding them how the medicine should be used and of the medicine’s possible side effects such as liver problems, thromboembolic complications and the recurrence of bleeding.
Desuden svandt 89,4 % af blødningsepisoderne efter en til to behandlinger med NovoEight.
In addition, 89.4% of the bleeding episodes resolved following 1 to 2 treatments with NovoEight.
Desuden svandt 95,2 % af blødningsepisoderne efter en til to behandlinger med NovoEight.
In addition, 95.2% of the bleeding episodes resolved following 1 to 2 treatments with NovoEight.
Desuden svarede den systemiske eksponering (AUCinf) for fri (ikke-liposom-associeret) MTP-PE hos personer med let eller moderat nyreinsufficiens til eksponeringen hos raske voksne forsøgspersoner med normal nyrefunktion.
Additionally, the systemic exposures (AUCinf) of free (non-liposome associated) MTP-PE in mild or moderate renal insufficiency were similar to those observed in healthy adult subjects with normal renal function.
Desuden sås gavnligt vægttab og lavere blodtryk.
In addition, beneficial reductions in weight and blood pressure were seen.